ERYTHROMYCIN
Generic: ERYTHROMYCIN
Zydus Pharmaceuticals USA Inc.Manufacturer
ORALRoute
ERYTHROMYCINActive Substance
2023-03-07Original Approval
ERYTHROMYCIN is FDA application ANDA212693, sponsored by ZYDUS LIFESCIENCES. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2026-04-29
Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intak
Class II2026-04-29
Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intak
Top Reported Reactions
1
DRUG HYPERSENSITIVITY
4,107 reports
2
NAUSEA
1,301 reports
3
VOMITING
1,136 reports
4
DRUG INEFFECTIVE
1,101 reports
5
DIARRHOEA
1,092 reports
6
DYSPNOEA
1,053 reports
7
FATIGUE
1,047 reports
8
RASH
1,033 reports
9
OFF LABEL USE
949 reports
10
HEADACHE
875 reports